BioTrak Therapeutics
Overview
BioTrak has developed the first therapeutic app for the 3 billion people worldwide who suffer from frequently recurring tension-type headaches & migraines. Ease(™) has been clinically-shown to reduce headache frequency & disability by as much as drugs, but without side effects. The Ease global launch will take place in Q1 ‘19; and BioTrak anticipates being cash flow positive by 2021.